Vermaat, J., Mutsaers, P., Anguille, S., Kuipers, M., Willems, E., Dekker, T., Vandenberghe, P., Dachy, G., Jacobson, C., Bishop, M., Dreyling, M., Klein, A., Arnason, J., Milatos, S., Kothari, H., Buglio, D., Blum, S., Chicaybam, L., Santermans, E., Fasan, O., Kersten, M. J. (2025). High complete response rates, low dropout rate, and low-grade toxicities in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) receiving GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 DLBCL cohort. Blood. https://doi.org/10.1182/blood-2025-5940